Eli Lilly (LLY) is planning to advertise its blockbuster weight loss drug, Zepbound, for the first time next month. Despite investor and industry recognition of the branded GLP-1 drug, "unaided ...

Eli Lilly, on the verge of the first consumer ad campaign for its Zepbound weight loss drug, has helped the Obesity Action ...

Aristotle Atlantic Partners, LLC, an investment advisor, released its “Large Cap Growth Strategy” third quarter 2024 investor ...

AP Health Writer (AP) — Eli Lilly is dialing back its 2024 forecast after underwhelming ... Advertisement Article continues below this ad The company brought in $3.1 billion in sales from Mounjaro and ...

AbbVie is reaching for the Sky(rizi) as it spent a staggering $51.5 million on TV drug ads for its immunology blockbuster in October. | AbbVie is reaching for the Sky(rizi) as it spent a staggering ...

The health technology assessment agency said that more evidence is needed on the clinical and cost-effectiveness of the drug Eli Lilly’s amyloid plaque-targeting Alzheimer’s disease (AD) drug has been ...

U.S. stock indexes edged lower after drops for Eli Lilly and chip companies overshadowed a jump for Google’s parent company.

According to a New York Times report this week, Eisai and Eli Lilly, in the clinical trials ... “The Clarity AD Informed Consent forms disclosed the known risks, including side effects and ...

Also Read: Eli Lilly’s Alzheimer’s Drug Raises Hopes ... Kisunla for adults with early symptomatic Alzheimer’s disease (AD), which includes people with mild cognitive impairment (MCI ...

Senators target online drug ad influencers in draft legislation ... Editor's note: This story was updated to include a statement from Eli Lilly.

Shares of Eli Lilly & Co. LLY inched 0.09% higher to $917.97 Friday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 0.40% to 5,864 ...